Form 4: Inovio Pharmaceuticals Executive Reports Stock Transactions
SEC Form 4 Filing
Michael John Sumner, Chief Medical Officer of Inovio Pharmaceuticals, reports the vesting of restricted stock units and subsequent tax withholding.
Summary
- On May 15, 2025, Michael John Sumner, Chief Medical Officer of Inovio Pharmaceuticals, had 2,385 restricted stock units vest.
- Following the vesting, shares were withheld by the issuer to satisfy tax obligations.
- Sumner now directly owns 14,934 shares of common stock.
Sentiment
Score: 5
Explanation: This is a routine filing related to executive compensation and tax obligations, and doesn't necessarily indicate positive or negative sentiment about the company's performance.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which can be an indicator of management's confidence in the company's future prospects. However, in this case, the sale was to cover tax obligations.
Stakeholder Impact
- The transaction has a minor impact on shareholders as it involves the vesting of previously granted equity.
Key Dates
| Date | Description |
|---|---|
| 05/15/2024 | 2,386 restricted stock units vested. |
| 05/15/2025 | 2,385 restricted stock units vested; tax withholding occurred. |
| 05/15/2026 | 2,385 restricted stock units will vest. |
| 05/16/2025 | Date of signature for the Form 4 filing. |
Keywords
Form 4, Inovio Pharmaceuticals, Stock Options, Restricted Stock Units, Beneficial Ownership, Michael John Sumner, INO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.